GlassScriptPhysician profile
Frederick M Malibiran
NPI 1215041769
$9,644.46
in general payments reported to CMS, 2019-2025
50 companies · $939 in 2025
The $939 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,859 · 2020: $2,013 · 2021: $1,736 · 2022: $1,194 · 2023: $711 · 2024: $1,192 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.56 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,281.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,092.44 | 2019-2025 | Airsupra, Breztri |
| Amarin Pharma, INC. | $714.91 | 2019-2022 | |
| Abbvie INC. | $663.45 | 2019-2025 | |
| Pfizer INC. | $561.71 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $532.90 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $452.68 | 2021-2025 | |
| Amgen INC. | $412.17 | 2019-2024 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $360.85 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $349.24 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $314.93 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Eisai INC. | $271.44 | 2020-2021 | |
| Allergan, INC. | $218.15 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $216.54 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $194.71 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Malibiran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.